Sacituzumab tirumotecan Antibody
Sacituzumab tirumotecan (SKB264) is a TROP2-targeting antibody-drug conjugate that delivers the topoisomerase I inhibitor KL610023 into tumor cells, inducing DNA damage and apoptosis. It is being investigated in preclinical and clinical research for TROP2-positive cancers, including non-small cell lung cancer and triple-negative breast cancer.
Product Specifications
Target
TROP2, Antibody-Drug Conjugates (ADCs)
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Concentration
15 mg/mL
Purity
99.00% (May vary between batches)
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog